Catalent ups its stake in ADC technology; Parexel: Sponsors prefer strategic partnerships;

> Catalent has upped its stake in Redwood Bioscience, a company that provides technology for producing antibody-drug conjugates. More

> According to a Parexel ($PRXL) survey, Big Pharma sponsors prefer deep-seated partnerships to transactional relationships with CROs. Item

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.